Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 7 member 6 (SLC7A6, also known as Y+L amino acid transporter 2 or Y+LAT2) is a plasma membrane transporter that forms a heterodimeric complex with SLC3A2 (4F2hc). It mediates the electroneutral exchange of cationic amino acids (such as L-arginine and L-lysine) for neutral amino acids (such as L-leucine and L-glutamine), with sodium-dependence for neutral amino acids. SLC7A6 is important for cellular uptake and efflux of amino acids, nitric oxide production, and ammonia clearance. Its overexpression is linked with enhanced amino acid uptake and signaling pathways promoting cancer growth. Dysfunction is implicated in disorders like lysinuric protein intolerance and cystinuria[1][2][3][4].
Transports/exchanges cationic and neutral amino acids across the plasma membrane, either sodium-independent (for cationic) or sodium-dependent (for neutral), functioning as an antiporter[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 7 member 6 (SLC7A6).